Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia 7Leukemia, Myeloid, Acute 6Medulloblastoma 5Lymphoma 5Sarcoma 4Hematologic Neoplasms 4Central Nervous System Neoplasms 4Brain Neoplasms 4Astrocytoma 4Rhabdoid Tumor 3Ovarian Neoplasms 3Glioma 3Ependymoma 3Burkitt Lymphoma 3Anemia, Refractory, with Excess of Blasts 3Wilms Tumor 2Rhabdomyosarcoma 2Retinoblastoma 2Primary Myelofibrosis 2Pinealoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Liver Neoplasms 2Leukemia, Myelomonocytic, Chronic 2

Interventions

fludarabine phosphate 3sargramostim 2Whole-Body Irradiation 2Mycophenolic Acid 2Cyclosporine 2Cyclophosphamide 2Azacitidine 24-phenylbutyric acid 2tipifarnib 1poly ICLC 1bryostatin 1 1aldesleukin 1Tretinoin 1Thiotepa 1Tetradecanoylphorbol Acetate 1Nivolumab 1Methylprednisolone 1Lenalidomide 1Injections 1Immunologic Techniques 1Granulocyte-Macrophage Colony-Stimulating Factor 1Decitabine 1Cord Blood Stem Cell Transplantation 1Bryostatins 1Biopsy 1Arsenic Trioxide 1Antilymphocyte Serum 14'-thio-arabinofuranosylcytosine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anemia, Refractory × Thiotepa × Clear all
NCT00376480 2019-07-05

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Dana-Farber Cancer Institute

Phase 1 Completed
19 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡